PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

Eligibility Criteria

• * Signed, informed consent
• * Age 18 or more years
• * Histologically confirmed, SCLC, (newly diagnosed or recurrent); small cell carcinoma of unknown or non-lung origin; or other types of neuroendocrine tumor OR
• * Histologically confirmed prostate cancer, with suspected or confirmed NEPC based upon clinical assays obtained prior to the trial
• * At least one tumor lesion on CT or MRI \>/= 2 cm
• * ECOG performance status 0 to 2
• * Negative serum pregnancy test within 2 weeks of 89Zr- DFO-SC16.56 or women of child-bearing potential
• * Adequate organ function as assessed by
• * Absolute neutrophil count (ANC) \>/= 1,500 mm\^8
• * Hemoglobin \>/= 8.0 g/dL
• * Platelet count \>/= 75,000/mm\^3
• * Bilirubin \</= 1.5 x ULN (upper limit of the norm)
• * AST (GOT) \</= 3.0 x ULN (when no liver metastases are present)
• * AST (GOT) \</= 5.0 x ULN (when liver metastases are present)
• * ALT (GOT) \</= 3.0 x ULN (when no liver metastases are present)
• * ALT (GOT) \</= 5.0 x ULN (when no liver metastases are present)
• * Creatinine \</= 1.5 x ULN
• * Available archival tumor biopsy material suitable for DLL3 IHC. Archival tissue is not required to have been collected within a specific time frame relative to imaging
• * For the prostate cancer patient cohort, as an alternative if archival tissue is not available, patients must be willing to undergo PET/CT guided biopsy\*\* as described in section 9.3.
• 1. Patients with SCLC will be the primary study population, however patients with other types of neuroendocrine tumors may be included at the PI's discretion.
• 2. Criterion is intended to demonstrate presence of imageable disease. A low-dose CT (e.g. from a PET/CT scan) may be used at PI's discretion
• 3. While willingness to undergo the biopsy is required if archival tissue is not available, PET/CT guided biopsy is not a mandatory study assessment. As described in section 9.3, the guided biopsy may be waived at the discretion of the principal investigator if the DLL3 PET/CT reveals no sites of DLL3 tracer-avid tumor or if the principal investigator deems it is not in the best interest of the patient, according to best clinical judgement.
• * History of anaphylactic reaction to humanize or human antibodies
• * Pregnant or breast feeding
• * Psychiatric illness that would interfere with compliance with the study procedures
• * Inability to undergo PET scan due to weight limit